We describe the case of a 16-year-old patient with refractory nephrotic syndrome (NS) diagnosed at the age of 6 years, notably with a heterozygous mutation of the ATG2A gene, who developed Crohn's disease (CD) following ten administrations of RTX. This evidence concerns the gene ATG2A and Netherton syndrome.